Therapies Targeting Exogenous Cholesterol Uptake: New Insights and Controversies
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapies Targeting Exogenous Cholesterol Uptake: New Insights and Controversies
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 13, Issue 1, Pages 95-100
Publisher
Springer Nature
Online
2010-12-28
DOI
10.1007/s11883-010-0151-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design
- (2010) Robert M. Califf et al. AMERICAN HEART JOURNAL
- Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1
- (2010) Quan Shang et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Transintestinal cholesterol efflux
- (2010) Astrid E van der Velde et al. CURRENT OPINION IN LIPIDOLOGY
- Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet
- (2010) D. C. Chan et al. DIABETES CARE
- The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)
- (2010) Todd C. Villines et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease
- (2010) Munechika Enjoji et al. Lipids in Health and Disease
- Ezetimibe prevents cholesterol gallstone formation in mice
- (2010) Silvia Zúñiga et al. LIVER INTERNATIONAL
- Moderately Decreased Cholesterol Absorption Rates Are Associated With a Large Atheroprotective Effect
- (2009) Michael E. Greenberg et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Niemann–Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter
- (2009) Harry R. Davis et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect
- (2009) D Gómez-Garre et al. BRITISH JOURNAL OF PHARMACOLOGY
- Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications
- (2009) M. H. DAVIDSON CLEVELAND CLINIC JOURNAL OF MEDICINE
- Bile salt sequestration induces hepaticde novolipogenesis through farnesoid X receptor- and liver X receptorα-controlled metabolic pathways in mice
- (2009) Hilde Herrema et al. HEPATOLOGY
- FXR an emerging therapeutic target for the treatment of atherosclerosis
- (2009) Andrea Mencarelli et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial
- (2009) L. Jakulj et al. JOURNAL OF LIPID RESEARCH
- Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
- (2009) Allen J. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cholesterol Absorption From the Intestine Is a Major Determinant of Reverse Cholesterol Transport From Peripheral Tissue Macrophages
- (2008) Ephraim Sehayek et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism
- (2008) Laura Calpe-Berdiel et al. ATHEROSCLEROSIS
- Does ENHANCE Diminish Confidence in Lowering LDL or in Ezetimibe?
- (2008) B. Greg Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started